Yikang Biotech (Suzhou) Co., Ltd.

Xiaoya Ding

Meng Zhang

Lei Chen

Li Chen

Chao Wu

Jiahao Xu

Peizhe Li

Mingze Shi

Jianguo Yin

Tengsen Gao

Shibi Zhao

Eric Chen

Songming He

Min Dai

Guangsha Zhang

Sufang Gu

Ruihong Jiang

Xin Xie

Derong Wang

Yujiao Song

Jiadi Huang

Tao Fang

Wendie Wang

Yujuan Hua

Jiaxin Lei

The present disclosure relates to the field of biomedicine, and in particular, to an improved mutant of a respiratory syncytial virus (RSV) fusion (F) protein and uses thereof. The mutant can form a trimeric structure without introducing a heterologous trimerization domain. Meanwhile, through mutation designs such as releasing internal electrostatic repulsion, deleting the furin cleavage site, truncating the C-terminal domain, and introducing interchain disulfide bonds, the protein is stabilized in the pre-fusion conformation and exhibits enhanced stability. The mutant in the present disclosure is highly immunogenic when used as a vaccine or a vaccine component and can induce the production of a high level of neutralizing antibodies in the immunized animal, which can be used in the preparation of a vaccine for the prevention or treatment of RSV infection, and can also be used as a reagent for the detection of RSV.

Mutants of respiratory syncytial virus fusion proteins

Growing community of inventors

Suzhou, China

Xiaoya Ding